Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells.

Simpkins F, Jang K, Yoon H, Hew K, Kim M, Azzam DJ, Sun J, Zhao D, Ince TA, Liu W, Guo W, Wei Z, Zhang G, Mills GB, Slingerland JM.

Clin Cancer Res. 2018 Jun 29. pii: clincanres.3697.2017. doi: 10.1158/1078-0432.CCR-17-3697. [Epub ahead of print]

PMID:
29959144
2.

A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.

Makvandi M, Pantel A, Schwartz L, Schubert E, Xu K, Hsieh CJ, Hou C, Kim H, Weng CC, Winters H, Doot R, Farwell MD, Pryma DA, Greenberg RA, Mankoff DA, Simpkins F, Mach RH, Lin LL.

J Clin Invest. 2018 May 1;128(5):2116-2126. doi: 10.1172/JCI97992. Epub 2018 Apr 16.

3.

BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.

Karakashev S, Zhu H, Yokoyama Y, Zhao B, Fatkhutdinov N, Kossenkov AV, Wilson AJ, Simpkins F, Speicher D, Khabele D, Bitler BG, Zhang R.

Cell Rep. 2017 Dec 19;21(12):3398-3405. doi: 10.1016/j.celrep.2017.11.095.

4.

Cancer-testis antigen expression is shared between epithelial ovarian cancer tumors.

Garcia-Soto AE, Schreiber T, Strbo N, Ganjei-Azar P, Miao F, Koru-Sengul T, Simpkins F, Nieves-Neira W, Lucci J 3rd, Podack ER.

Gynecol Oncol. 2017 Jun;145(3):413-419. doi: 10.1016/j.ygyno.2017.03.512. Epub 2017 Apr 6.

PMID:
28392126
5.

Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma.

Rose PG, Ali S, Moslemi-Kebria M, Simpkins F.

Int J Gynecol Cancer. 2017 Mar;27(3):452-458. doi: 10.1097/IGC.0000000000000891.

PMID:
28187088
6.

VEGFA activates an epigenetic pathway upregulating ovarian cancer-initiating cells.

Jang K, Kim M, Gilbert CA, Simpkins F, Ince TA, Slingerland JM.

EMBO Mol Med. 2017 Mar;9(3):304-318. doi: 10.15252/emmm.201606840.

7.

The role of Nrf2 and ATF2 in resistance to platinum-based chemotherapy.

Chen J, Solomides C, Simpkins F, Simpkins H.

Cancer Chemother Pharmacol. 2017 Feb;79(2):369-380. doi: 10.1007/s00280-016-3225-1. Epub 2017 Jan 24.

PMID:
28120035
8.

A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers.

George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R, Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F.

JCI Insight. 2017 Jan 12;2(1):e89760. doi: 10.1172/jci.insight.89760.

9.

Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models.

Kim H, George E, Ragland R, Rafial S, Zhang R, Krepler C, Morgan M, Herlyn M, Brown E, Simpkins F.

Clin Cancer Res. 2017 Jun 15;23(12):3097-3108. doi: 10.1158/1078-0432.CCR-16-2273. Epub 2016 Dec 19.

10.

RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.

Wang Y, Krais JJ, Bernhardy AJ, Nicolas E, Cai KQ, Harrell MI, Kim HH, George E, Swisher EM, Simpkins F, Johnson N.

J Clin Invest. 2016 Aug 1;126(8):3145-57. doi: 10.1172/JCI87033. Epub 2016 Jul 25.

11.

Race-based disparities in loss of functional independence after hysterectomy for uterine cancer.

Dean LT, Zhang X, Latif N, Giuntoli R, Lin L, Haggerty A, Kim S, Shalowitz D, Stashwick C, Simpkins F, Burger R, Morgan M, Ko E, Schmitz K.

Support Care Cancer. 2016 Aug;24(8):3573-80. doi: 10.1007/s00520-016-3185-3. Epub 2016 Mar 30.

12.

MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.

Hew KE, Miller PC, El-Ashry D, Sun J, Besser AH, Ince TA, Gu M, Wei Z, Zhang G, Brafford P, Gao W, Lu Y, Mills GB, Slingerland JM, Simpkins F.

Clin Cancer Res. 2016 Feb 15;22(4):935-47. doi: 10.1158/1078-0432.CCR-15-0534. Epub 2015 Oct 19.

13.

The prescription or proscription of exercise in endometrial cancer care.

Zhang X, Haggerty AF, Brown JC, Giuntoli R 2nd, Lin L, Simpkins F, Dean LT, Ko E, Morgan MA, Schmitz KH.

Gynecol Oncol. 2015 Oct;139(1):155-9. doi: 10.1016/j.ygyno.2015.08.007. Epub 2015 Aug 22.

14.

Cisplatin resistance in human cervical, ovarian and lung cancer cells.

Chen J, Solomides C, Parekh H, Simpkins F, Simpkins H.

Cancer Chemother Pharmacol. 2015 Jun;75(6):1217-27. doi: 10.1007/s00280-015-2739-2. Epub 2015 Apr 18.

PMID:
25894720
15.

A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA).

Simpkins F, Drake R, Escobar PF, Nutter B, Rasool N, Rose PG.

Gynecol Oncol. 2015 Feb;136(2):240-5. doi: 10.1016/j.ygyno.2014.12.004. Epub 2014 Dec 6.

PMID:
25485782
16.

Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study.

Simpkins F, Flores A, Chu C, Berek JS, Lucci J 3rd, Murray S, Bauman J, Struemper H, Germaschewski F, Jonak Z, Gardner O, Toso J, Coukos G.

Cancer Immunol Res. 2013 Sep;1(3):168-78. doi: 10.1158/2326-6066.CIR-13-0098. Epub 2013 Jul 31.

17.

New insights on the role of hormonal therapy in ovarian cancer.

Simpkins F, Garcia-Soto A, Slingerland J.

Steroids. 2013 Jun;78(6):530-7. doi: 10.1016/j.steroids.2013.01.008. Epub 2013 Feb 8. Review.

18.

Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular space invasion.

Simpkins F, Papadia A, Kunos C, Michener C, Frasure H, AbuShahin F, Mariani A, Bakkum-Gamez JN, Landrum L, Moore K, Thomas SG, Windhorn A, Rose PG.

Int J Gynecol Cancer. 2013 Jan;23(1):98-104. doi: 10.1097/IGC.0b013e318276d9b6.

PMID:
23221731
19.

Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.

Simpkins F, Hevia-Paez P, Sun J, Ullmer W, Gilbert CA, da Silva T, Pedram A, Levin ER, Reis IM, Rabinovich B, Azzam D, Xu XX, Ince TA, Yang JY, Verhaak RG, Lu Y, Mills GB, Slingerland JM.

Clin Cancer Res. 2012 Nov 1;18(21):5911-23. doi: 10.1158/1078-0432.CCR-12-1257. Epub 2012 Aug 15.

20.

A Phase I Study using low-dose fractionated whole abdominal radiotherapy as a chemopotentiator to full-dose cisplatin for optimally debulked stage III/IV carcinoma of the endometrium.

Wrenn DC, Saigal K, Lucci JA 3rd, Pearson MJ, Simpkins F, Schuman S, Twiggs LB, Walker GR, Wolfson AH.

Gynecol Oncol. 2011 Jul;122(1):59-62. doi: 10.1016/j.ygyno.2011.03.007. Epub 2011 Apr 6.

PMID:
21474169
21.

Nuclear envelope structural defects cause chromosomal numerical instability and aneuploidy in ovarian cancer.

Capo-chichi CD, Cai KQ, Simpkins F, Ganjei-Azar P, Godwin AK, Xu XX.

BMC Med. 2011 Mar 26;9:28. doi: 10.1186/1741-7015-9-28.

22.

Frozen section underestimates the need for surgical staging in endometrial cancer patients.

Papadia A, Azioni G, BrusacĂ  B, Fulcheri E, Nishida K, Menoni S, Simpkins F, Lucci JA 3rd, Ragni N.

Int J Gynecol Cancer. 2009 Dec;19(9):1570-3. doi: 10.1111/IGC.0b013e3181bff64b.

PMID:
19955939
23.

Radiation therapy compared with pelvic node resection for node-positive vulvar cancer: a randomized controlled trial.

Kunos C, Simpkins F, Gibbons H, Tian C, Homesley H.

Obstet Gynecol. 2009 Sep;114(3):537-46. doi: 10.1097/AOG.0b013e3181b12f99.

PMID:
19701032
24.

Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo.

Devoogdt N, Rasool N, Hoskins E, Simpkins F, Tchabo N, Kohn EC.

Cancer Sci. 2009 Mar;100(3):434-40. doi: 10.1111/j.1349-7006.2009.01076.x. Epub 2009 Jan 14.

25.

Chemotherapy Administration during Pelvic Radiation for Cervical Cancer Patients Aged >/=55 Years in the SEER-Medicare Population.

Kunos C, Gibbons H, Simpkins F, Waggoner S.

J Oncol. 2008;2008:931532. doi: 10.1155/2008/931532. Epub 2008 Aug 27.

26.

The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells.

Simpkins FA, Devoogdt NM, Rasool N, Tchabo NE, Alejandro EU, Kamrava MM, Kohn EC.

Carcinogenesis. 2008 Mar;29(3):466-72. Epub 2007 Oct 4.

PMID:
17916899
27.

Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.

Simpkins F, Belinson JL, Rose PG.

Gynecol Oncol. 2007 Oct;107(1):118-23. Epub 2007 Jul 23.

PMID:
17658587
28.

SELDI-TOF mass spectrometry for cancer biomarker discovery and serum proteomic diagnostics.

Simpkins F, Czechowicz JA, Liotta L, Kohn EC.

Pharmacogenomics. 2005 Sep;6(6):647-53.

PMID:
16143004
29.
30.

Ovarian malignancy in breast cancer patients with an adnexal mass.

Simpkins F, Zahurak M, Armstrong D, Grumbine F, Bristow R.

Obstet Gynecol. 2005 Mar;105(3):507-13. Review.

PMID:
15738016
31.

Proteomic analysis for the early detection and rational treatment of cancer--realistic hope?

Posadas EM, Simpkins F, Liotta LA, MacDonald C, Kohn EC.

Ann Oncol. 2005 Jan;16(1):16-22. Review.

PMID:
15598930
32.

Rapid Quantitative Analysis of Individual (18)FDG-PET Scans.

Swartz BE, Thomas K, Simpkins F, Kovalik E, Mandelkern MM.

Clin Positron Imaging. 1999 Jan;2(1):47-56.

PMID:
14516553
33.

Positron emission tomography for detecting clinically occult surgically resectable metastatic ovarian cancer.

Bristow RE, Simpkins F, Pannu HK, Fishman EK, Montz FJ.

Gynecol Oncol. 2002 Apr;85(1):196-200.

PMID:
11925145
34.

Visual working memory in primary generalized epilepsy: an 18FDG-PET study.

Swartz BE, Simpkins F, Halgren E, Mandelkern M, Brown C, Krisdakumtorn T, Gee M.

Neurology. 1996 Nov;47(5):1203-12.

PMID:
8909431
35.

Primary or working memory in frontal lobe epilepsy: An 18FDG-PET study of dysfunctional zones.

Swartz BE, Halgren E, Simpkins F, Fuster J, Mandelkern M, Krisdakumtorn T, Gee M, Brown C, Ropchan JR, Blahd WH.

Neurology. 1996 Mar;46(3):737-47.

PMID:
8618675
36.

Studies of working memory using 18FDG-positron emission tomography in normal controls and subjects with epilepsy.

Swartz BE, Halgren E, Simpkins F, Mandelkern M.

Life Sci. 1996;58(22):2057-64.

PMID:
8637437
37.

Improved sensitivity of 18FDG-positron emission tomography scans in frontal and "frontal plus" epilepsy.

Swartz BW, Khonsari A, Vrown C, Mandelkern M, Simpkins F, Krisdakumtorn T.

Epilepsia. 1995 Apr;36(4):388-95.

PMID:
7607118

Supplemental Content

Loading ...
Support Center